Selective inhibition of BET bromodomains

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237 · see citing works

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,618 · see citing works

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445 · see citing works

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420 · see citing works

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785 · see citing works

c-Myc Regulates Transcriptional Pause Release

Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279 · see citing works

Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4

Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,141 · see citing works

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,060 · see citing works

Bromodomain: an acetyl‐lysine binding domain

Zeng, L., & Zhou, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 751 · see citing works

Control of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase

Marshall, N. F., Peng, J., Xie, Z., & Price, D. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.27176 · Cited by 662 · see citing works

Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA

Huang, B., Yang, X., Zhou, M., Ozato, K., & Chen, L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01365-08 · Cited by 586 · see citing works

Purification of P-TEFb, a Transcription Factor Required for the Transition into Productive Elongation

Marshall, N. F., & Price, D. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12335 · Cited by 564 · see citing works

The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase Gcn5p

Owen, D. J., Ornaghi, P., Yang, J., Lowe, N., Evans, P. R., Ballario, P., Neuhaus, D., Filetici, P., & TRAVERS, A. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.22.6141 · Cited by 543 · see citing works

Identification of multiple cyclin subunits of human P-TEFb.Preprint

Peng, J.-M., Zhu, Y., Milton, J. T., & Price, D. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 531 · see citing works

BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 503 · see citing works

BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells

French, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E., Kutok, J. L., Toretsky, J. A., Tadavarthy, A. K., Kees, U. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210852 · Cited by 441 · see citing works

Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody

Haack, H., Johnson, L. A., Fry, C. J., et al. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318198d666 · Cited by 435 · see citing works

Signaling Network Model of Chromatin

Schreiber, S. L., & Bernstein, B. (2002) · Cell · doi:10.1016/s0092-8674(02)01196-0 · Cited by 395 · see citing works

The art of the chemical probe

Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375 · see citing works

In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor

le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., & Gambacorti-Passerini, C. B. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.163 · Cited by 372 · see citing works

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases

Fedorov, O., Marsden, B. D., Pogačić, V., Rellos, P., Müller, S., Bullock, A. N., Schwaller, J., Sundström, M., & Knapp, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708800104 · Cited by 361 · see citing works

Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G 1 Gene Expression and Cell Cycle Progression

Yang, Z., He, N., & Zhou, Q. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01020-07 · Cited by 349 · see citing works

Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription

Dey, A., Nishiyama, A., Karpova, T., McNally, J. G., & Ozato, K. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-05-0380 · Cited by 319 · see citing works

A Bromodomain Protein, MCAP, Associates with Mitotic Chromosomes and Affects G2-to-M Transition

Dey, A., Ellenberg, J., Farina, A., Coleman, A., Maruyama, T., Sciortino, S., Lippincott‐Schwartz, J., & Ozato, K. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.17.6537-6549.2000 · Cited by 304 · see citing works

Multisite protein modification and intramolecular signaling

Yang, X. (2004) · Oncogene · doi:10.1038/sj.onc.1208173 · Cited by 267 · see citing works

Chemical probes for histone-modifying enzymes

Cole, P. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.111 · Cited by 249 · see citing works

BRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19)

French, C. A., Miyoshi, I., Aster, J. C., Kubonishi, I., Kroll, T. G., Cin, P. D., Vargas, S. O., Pérez‐Atayde, A. R., & Fletcher, J. A. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63049-0 · Cited by 204 · see citing works

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Phelps, M. A., Lin, T. S., Johnson, A. J., Hurh, E., Rozewski, D. M., Farley, K. L., Wu, D., Blum, K. A., Fischer, B., Mitchell, S. M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-168583 · Cited by 156 · see citing works

Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase

Bullock, A. N., Debreczeni, J. E., Fedorov, O., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0504858 · Cited by 151 · see citing works

Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Interacts with Bromodomain Protein Brd4 on Host Mitotic Chromosomes

You, J., Srinivasan, V., Denis, G. V., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00502-06 · Cited by 146 · see citing works

Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution

Vollmuth, F., Blankenfeldt, W., & Geyer, M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033712 · Cited by 137 · see citing works

Activation of chromatin by acetylation of histone side chains.

Marushige, K. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3937 · Cited by 137 · see citing works

Structure of the Papillomavirus DNA-Tethering Complex E2:Brd4 and a Peptide that Ablates HPV Chromosomal Association

Abbate, E. A., Voitenleitner, C., & Botchan, M. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.002 · Cited by 120 · see citing works

A crowdsourcing evaluation of the NIH chemical probes

Oprea, T. I., Bologa, C., Boyer, S. K., Curpan, R. F., Glen, R. C., Hopkins, A. L., Lipinski, C. A., Marshall, G. R., Martin, Y. C., Halip, L., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0709-441 · Cited by 111 · see citing works

Regulation of Aurora B Expression by the Bromodomain Protein Brd4

You, J., Li, Q., Wu, C., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00299-09 · Cited by 70 · see citing works

Translocation (11;15;19): a Highly Specific Chromosome Rearrangement Associated With Poorly Differentiated Thymic Carcinoma in Young Patients

Toretsky, J. A., Jenson, J., Sun, C. J., et al. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000020960.98562.84 · Cited by 68 · see citing works

A homogeneous method for investigation of methylation-dependent protein-protein interactions in epigenetics

Quinn, A. M., Bedford, M. T., Espejo, A. B., Spannhoff, A., Austin, C. P., Oppermann, U. C. T., & Simeonov, A. M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp899 · Cited by 54 · see citing works

Binding reactions: epigenetic switches, signal transduction and cancer

Ptashne, M. (2009) · Current Biology · doi:10.1016/j.cub.2009.02.015 · Cited by 44 · see citing works

Alprazolam: Review of pharmacological, pharmacokinetic, and clinical data

VonVoigtlander, P. F., & Straw, R. N. (1985) · Drug Development Research · doi:10.1002/ddr.430060102 · Cited by 31 · see citing works

Cancer epigenetics: from mechanism to therapy

Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · see citing works

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · see citing works

A decade of exploring the cancer epigenome—biological and translational implications

Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · see citing works

The molecular hallmarks of epigenetic control

Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works

MYC regulates the antitumor immune response through CD47 and PD-L1

Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403 · see citing works

The growing landscape of lysine acetylation links metabolism and cell signalling

Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324 · see citing works

Cellular Senescence: Aging, Cancer, and Injury

Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270 · see citing works

Epigenetic protein families: a new frontier for drug discovery

Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · see citing works

Functions and mechanisms of non-histone protein acetylation

Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140 · see citing works

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137 · see citing works

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · see citing works

The dTAG system for immediate and target-specific protein degradation

Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118 · see citing works

Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality

Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065 · see citing works

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · see citing works

Targeting transcription factors in cancer — from undruggable to reality

Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919 · see citing works

Drugging the ‘undruggable’ cancer targets

Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927 · see citing works

ATP-dependent chromatin remodeling: genetics, genomics and mechanisms

Hargreaves, D. C., & Crabtree, G. R. (2011) · Cell Research · doi:10.1038/cr.2011.32 · Cited by 923 · see citing works

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852 · see citing works

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science · doi:10.1126/science.1259037 · Cited by 801 · see citing works

Small‐Molecule PROTACS: New Approaches to Protein Degradation

Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674 · see citing works

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · see citing works

Plasticity in binding confers selectivity in ligand-induced protein degradation

Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615 · see citing works

BET inhibitor resistance emerges from leukaemia stem cells

Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · see citing works

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546 · see citing works

Phenotypic screening in cancer drug discovery — past, present and future

Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507 · see citing works

The discovery of first-in-class drugs: origins and evolution

Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514 · see citing works

Chemically induced proximity in biology and medicine

Stanton, B. Z., Chory, E. J., & Crabtree, G. R. (2018) · Science · doi:10.1126/science.aao5902 · Cited by 475 · see citing works

Genome-Informed Targeted Therapy for Osteosarcoma

Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452 · see citing works

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487 · see citing works

Differentiation therapy revisited

de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462 · see citing works

BET Proteins as Targets for Anticancer Treatment

Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463 · see citing works

Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated <i>Myc</i> regulation

Shi, J., Whyte, W. A., Zepeda-Mendoza, C. J., Milazzo, J. P., Shen, C., Roe, J.-S., Minder, J. L., Mercan, F., Wang, E., Eckersley-Maslin, M. A., et al. (2013) · Genes &amp; Development · doi:10.1101/gad.232710.113 · Cited by 463 · see citing works

Epigenetic mechanisms in neurological disease

Jakovcevski, M., & Akbarian, S. (2012) · Nature Medicine · doi:10.1038/nm.2828 · Cited by 450 · see citing works

The emerging role of epigenetic therapeutics in immuno-oncology

Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · see citing works

BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance

Tasdemir, N., Banito, A., Roe, J.-S., Alonso-Curbelo, D., Camiolo, M., Tschaharganeh, D. F., Huang, C.-H., Aksoy, O., Bolden, J. E., Chen, C.-C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0217 · Cited by 415 · see citing works

Drugging the undruggables: exploring the ubiquitin system for drug development

Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427 · see citing works

BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure

Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406 · see citing works

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Faivre, E. J., McDaniel, K. F., Albert, D. H., Mantena, S. R., Plotnik, J. P., Wilcox, D., Zhang, L., Bui, M. H., Sheppard, G. S., Wang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-1930-8 · Cited by 408 · see citing works

Targeting protein–protein interactions as an anticancer strategy

Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401 · see citing works

Regulation of cancer cell metabolism: Oncogenic MYC in the driver’s seat

Dong, Y., Tu, R., Liu, H., & Qing, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00235-2 · Cited by 405 · see citing works

Light-Induced Protein Degradation with Photocaged PROTACs

Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377 · see citing works

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348 · see citing works

Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors

Andricovich, J., Perkail, S., Kai, Y., Casasanta, N., Peng, W., & Tzatsos, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.003 · Cited by 320 · see citing works

WD40 repeat domain proteins: a novel target class?

Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335 · see citing works

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Ward, C. C., Kleinman, J. I., Brittain, S. M., Lee, P. S., Chung, C. Y. S., Kim, K., Petri, Y., Thomas, J. R., Tallarico, J. A., McKenna, J. M., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01083 · Cited by 336 · see citing works

Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases

Watanabe, S., Kawamoto, S., Ohtani, N., & Hara, E. (2017) · Cancer Science · doi:10.1111/cas.13184 · Cited by 321 · see citing works

Marked for death: Targeting epigenetic changes in cancer

Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281 · see citing works

BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure

Duan, Q., McMahon, S., Anand, P., Shah, H., Thomas, S., Salunga, H. T., Huang, Y., Zhang, R., Sahadevan, A., Lemieux, M. E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5084 · Cited by 262 · see citing works

Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function

Sakamaki, J.-I., Wilkinson, S., Hahn, M., Tasdemir, N., O’Prey, J., Clark, W., Hedley, A., Nixon, C., Long, J. S., New, M., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.027 · Cited by 249 · see citing works

Clinical trials for BET inhibitors run ahead of the science

Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247 · see citing works

A transcriptional switch governs fibroblast activation in heart disease

Alexanian, M., Przytycki, P. F., Micheletti, R., Padmanabhan, A., Ye, L., Travers, J. G., Gonzalez-Teran, B., Silva, A. C., Duan, Q., Ranade, S. S., et al. (2021) · Nature · doi:10.1038/s41586-021-03674-1 · Cited by 238 · see citing works

Metabolic regulation of chromatin modifications and gene expression

Schvartzman, J. M., Thompson, C. B., & Finley, L. W. S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803061 · Cited by 233 · see citing works

Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity

Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00878-4 · Cited by 251 · see citing works

RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

Cheng, J. X., Chen, L., Li, Y., Cloe, A., Yue, M., Wei, J., Watanabe, K. A., Shammo, J. M., Anastasi, J., Shen, Q. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03513-4 · Cited by 204 · see citing works

Targeted protein degradation via intramolecular bivalent glues

Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222 · see citing works

Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands

Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222 · see citing works

Biological plasticity rescues target activity in CRISPR knock outs

Smits, A. H., Ziebell, F., Joberty, G., Zinn, N., Mueller, W. F., Clauder-Münster, S., Eberhard, D., Fälth Savitski, M., Grandi, P., Jakob, P., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0614-5 · Cited by 219 · see citing works

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2306 · Cited by 224 · see citing works

BRD4 is a novel therapeutic target for liver fibrosis

Ding, N., Hah, N., Yu, R. T., Sherman, M. H., Benner, C., Leblanc, M., He, M., Liddle, C., Downes, M., & Evans, R. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522163112 · Cited by 211 · see citing works

Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic

Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231 · see citing works

Targeted Protein Degradation by Small Molecules

Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207 · see citing works

Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity

Pillow, T. H., Adhikari, P., Blake, R. A., Chen, J., Del Rosario, G., Deshmukh, G., Figueroa, I., Gascoigne, K. E., Kamath, A. V., Kaufman, S., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900497 · Cited by 216 · see citing works

Targeting Protein-Protein Interaction by Small Molecules

Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195 · see citing works

BET proteins promote efficient murine leukemia virus integration at transcription start sites

Sharma, A., Larue, R. C., Plumb, M. R., Malani, N., Male, F., Slaughter, A., Kessl, J. J., Shkriabai, N., Coward, E., Aiyer, S. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307157110 · Cited by 193 · see citing works

<i>In Silico</i> Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application

Drummond, M. L., & Williams, C. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00872 · Cited by 199 · see citing works

Place your BETs: the therapeutic potential of bromodomains

Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197 · see citing works

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199 · see citing works

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180 · see citing works

Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation

Stratton, M. S., Bagchi, R. A., Felisbino, M. B., Hirsch, R. A., Smith, H. E., Riching, A. S., Enyart, B. Y., Koch, K. A., Cavasin, M. A., Alexanian, M., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315125 · Cited by 179 · see citing works

Role of MYC in medulloblastoma

Roussel, M. F., & Robinson, G. W. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014308 · Cited by 180 · see citing works

The BET Family of Proteins Targets Moloney Murine Leukemia Virus Integration near Transcription Start Sites

De Rijck, J., de Kogel, C., Demeulemeester, J., Vets, S., El Ashkar, S., Malani, N., Bushman, F. D., Landuyt, B., Husson, S. J., Busschots, K., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.040 · Cited by 175 · see citing works

BET acetyl-lysine binding proteins control pathological cardiac hypertrophy

Spiltoir, J. I., Stratton, M. S., Cavasin, M. A., Demos-Davies, K., Reid, B. G., Qi, J., Bradner, J. E., & McKinsey, T. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.07.017 · Cited by 174 · see citing works

Identifying drug targets in tissues and whole blood with thermal-shift profiling

Perrin, J., Werner, T., Kurzawa, N., Rutkowska, A., Childs, D. D., Kalxdorf, M., Poeckel, D., Stonehouse, E., Strohmer, K., Heller, B., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0388-4 · Cited by 178 · see citing works

Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery

Greer, C. B., Tanaka, Y., Kim, Y. J., Xie, P., Zhang, M. Q., Park, I.-H., & Kim, T. H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.013 · Cited by 174 · see citing works

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

Dragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Chen, J., Corr, N., dela Cruz-Chuh, J., Del Rosario, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01846 · Cited by 174 · see citing works

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor

Palmer, W. S., Poncet-Montange, G., Liu, G., Petrocchi, A., Reyna, N., Subramanian, G., Theroff, J., Yau, A., Kost-Alimova, M., Bardenhagen, J. P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00405 · Cited by 168 · see citing works

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence

Morrow, J. J., Bayles, I., Funnell, A. P. W., Miller, T. E., Saiakhova, A., Lizardo, M. M., Bartels, C. F., Kapteijn, M. Y., Hung, S., Mendoza, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4475 · Cited by 161 · see citing works

Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties

Bigdeli, A., Palchetti, S., Pozzi, D., Hormozi-Nezhad, M. R., Baldelli Bombelli, F., Caracciolo, G., & Mahmoudi, M. (2016) · ACS Nano · doi:10.1021/acsnano.6b00261 · Cited by 157 · see citing works

Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation

Roy, N., Malik, S., Villanueva, K. E., Urano, A., Lu, X., Von Figura, G., Seeley, E. S., Dawson, D. W., Collisson, E. A., & Hebrok, M. (2015) · Genes &amp; Development · doi:10.1101/gad.256628.114 · Cited by 155 · see citing works

Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta

Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157 · see citing works

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties

Dragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Bhakta, S., Blaquiere, N., Chen, J., dela Cruz-Chuh, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01845 · Cited by 152 · see citing works

Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration

Gupta, S. S., Maetzig, T., Maertens, G. N., Sharif, A., Rothe, M., Weidner-Glunde, M., Galla, M., Schambach, A., Cherepanov, P., & Schulz, T. F. (2013) · Journal of Virology · doi:10.1128/jvi.01942-13 · Cited by 139 · see citing works

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer

Li, X., Baek, G., Ramanand, S. G., Sharp, A., Gao, Y., Yuan, W., Welti, J., Rodrigues, D. N., Dolling, D., Figueiredo, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.078 · Cited by 148 · see citing works

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Wei, J., Meng, F., Park, K.-S., Yim, H., Velez, J., Kumar, P., Wang, L., Xie, L., Chen, H., Shen, Y., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04841 · Cited by 154 · see citing works

Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity

Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01496 · Cited by 152 · see citing works

An iridium( <scp>iii</scp> )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent

Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138 · see citing works

Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis

Nishida, J., Momoi, Y., Miyakuni, K., Tamura, Y., Takahashi, K., Koinuma, D., Miyazono, K., & Ehata, S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0491-2 · Cited by 135 · see citing works

Chemoproteomics and Chemical Probes for Target Discovery

Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132 · see citing works

Chromatin remodelling drives immune cell–fibroblast communication in heart failure

Alexanian, M., Padmanabhan, A., Nishino, T., Travers, J. G., Ye, L., Pelonero, A., Lee, C. Y., Sadagopan, N., Huang, Y., Auclair, K., et al. (2024) · Nature · doi:10.1038/s41586-024-08085-6 · Cited by 140 · see citing works

Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy

Liang, K., Smith, E. R., Aoi, Y., Stoltz, K. L., Katagi, H., Woodfin, A. R., Rendleman, E. J., Marshall, S. A., Murray, D. C., Wang, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.027 · Cited by 124 · see citing works

Targeting protein–protein interactions, a wide open field for drug design

Bakail, M., & Ochsenbein, F. (2016) · Comptes Rendus. Chimie · doi:10.1016/j.crci.2015.12.004 · Cited by 117 · see citing works

iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein–protein interactions

Labbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104 · see citing works

Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining

Stanlie, A., Yousif, A. S., Akiyama, H., Honjo, T., & Begum, N. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.018 · Cited by 101 · see citing works

PROTAC degraders as chemical probes for studying target biology and target validation

Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98 · see citing works

Novel immunomodulatory drugs and neo-substrates

Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95 · see citing works

Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma

Zhang, X., Zegar, T., Lucas, A., Morrison-Smith, C. D., Knox, T. M., French, C. A., Knapp, S., Müller, S., & Siveke, J. T. (2020) · Oncogene · doi:10.1038/s41388-020-1301-9 · Cited by 46 · see citing works

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Morrison-Smith, C. D., Knox, T. M., Filic, I., Soroko, K. M., Eschle, B. K., Wilkens, M. K., Gokhale, P. C., Giles, F. J., Griffin, A. M., Brown, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0087 · Cited by 86 · see citing works

PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains

Picaud, S., Costa, D. D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P. E., Bunnage, M. E., Owen, D. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3292 · Cited by 251 · see citing works

Data from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Morrison-Smith, C. D., Knox, T. M., Filic, I., et al. (2023) · doi:10.1158/1535-7163.c.6542821

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Sperandio, D., Aktoudianakis, V., Babaoglu, K., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.020 · Cited by 17 · see citing works